Needham & Company LLC Reiterates "Hold" Rating for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report)'s stock had its "hold" rating reissued by Needham & Company LLC in a report issued on Thursday,Benzinga reports.

Separately, Piper Sandler cut their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st.

Amphastar Pharmaceuticals Stock Performance

Shares of Amphastar Pharmaceuticals stock traded down $0.72 on Thursday, hitting $23.70. 325,819 shares of the company's stock were exchanged, compared to its average volume of 456,963. Amphastar Pharmaceuticals has a 1 year low of $22.60 and a 1 year high of $53.96. The company has a 50-day simple moving average of $28.51 and a 200-day simple moving average of $37.90. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock has a market capitalization of $1.13 billion, a PE ratio of 7.90, a PEG ratio of 2.19 and a beta of 0.79.

Insider Transactions at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares of the company's stock, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 27.10% of the company's stock.

Remove Ads

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC grew its position in shares of Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after purchasing an additional 493 shares in the last quarter. Parkside Financial Bank & Trust grew its holdings in Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after buying an additional 871 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Amphastar Pharmaceuticals in the 4th quarter worth approximately $38,000. GAMMA Investing LLC raised its holdings in shares of Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after acquiring an additional 424 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after acquiring an additional 348 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.